

SYNTHESIS AND ACETYLCHOLINESTERASE/BUTYRYLCHOLINESTERASE INHIBITION ACTIVITY OF ARECOLINE-, 4-THIAZOLIDINONE- AND PIPERIDINE- BASED CONJUGATES**KOTHANAHALLY SHIVARAMU SHARATH KUMAR¹, CHAKRABHAVI DHANANJAYA MOHAN¹,
SWAMY JAGADISH¹, KODAGAHALLI SATHYA RAKESH¹, ANANDA HANUMAPPA¹, BASAPPA²,
KANCHUGARAKOPPAL SUBBEGOWDA RANGAPPA^{1*}**¹Department of Studies in Chemistry, Manasagangotri, University of Mysore, Mysore - 570 006, Karnataka, India. ²Department of Chemistry, Bangalore University, Bengaluru, Karnataka, India. Email: rangappaks@gmail.com

Received: 14 August 2014, Revised and Accepted: 13 September 2014

ABSTRACT**Objective:** The aim of the study is to design, synthesize and identification of novel acetylcholinesterase/butyrylcholinesterase (AChE/BuChE) inhibitors.**Methods:** The AChE and BuChE inhibition activity of a library of piperidine and 4-thiazolidinone substituted arecoline derivatives are described. The chemical structures of newly synthesized compounds were confirmed by IR, ¹H NMR, ¹³C NMR and mass spectral analysis.**Results:** The cholinesterase inhibition assays indicated that few of the synthesized compounds exhibited considerable activity at micromolar range for AChE over BuChE. Compound 7c exhibited the most potent AChE inhibitory activity with an IC₅₀ value of 6.62 μM for AChE and 13.78 μM for BuChE, which is comparable to the standard Neostigmine with an IC₅₀ 2.05 μM for AChE and 3.64 μM for BuChE respectively.**Conclusion:** Our results clearly demonstrate that arecoline-4-thiazolidinone derivatives open up a new avenue in the field of Alzheimer's disease.**Keywords:** Arecoline analogs, Propylphosphonic anhydride (T3P®), Acetylcholinesterase/butyrylcholinesterase inhibitor, 4-thiazolidinones.**INTRODUCTION**

Alzheimer's disease (AD) is one of the most predominant irreversible neurodegenerative diseases associated with age advancement that is characterized by progressive memory loss due to neuronal deterioration and cognitive dysfunction [1]. AD develops gradually and may remain masked for several years without a diagnosis. Dysfunction of the cholinergic system, aggregation of amyloid beta proteins, hyperphosphorylation of tau proteins are the major causes of AD [2]. In humans, the pivotal signaling molecule of cholinergic transmission is acetylcholine (ACh), which is one of the prime neurotransmitters with the dual role of excitatory and inhibitory neurotransmission [3]. It majorly operates at neuromuscular junction, central nervous system and synapses in the ganglia [4]. Levels of ACh at the cholinergic synapse are regulated by cholinesterases that include acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) [5]. AChE rapidly degrades the ACh into acetate and choline, thus terminates the nerve impulse transmission [6].

According to the cholinergic hypothesis, reduction of ACh is a responsible for the development of AD [7]. Inhibition of AChE could be a better strategy in improving the cognitive capacity of the AD patient [8]. The role of BuChE is not very clear but thought to be involved in the hydrolysis of ACh. In the normal conditions, AChE levels in the brain are higher than BuChE. On the contrary, AD Patients suffers from a substantial decline in the concentration of AChE and BuChE concentration remains same or may increase progressively. Furthermore, in the last few decades, cholinesterase inhibitors are the extensively used medications to prevent the advancement of AD [9]. Synthetic compounds like donepezil, tacrine, rivastigmine and galanthamine (Fig. 1), a natural alkaloid are the US-Food and Drug Administration approved cholinesterase inhibitors used to treat AD patients [10-12]. Therefore, targeting of cholinesterases is considered to be very effective in designing and formulating the therapeutic agent to break the progression of AD.

Arecoline is a natural alkaloid present in the arecanut, and it is known for its effective cognition skills enhancing effects in patients with AD and so arecoline derivatives have been considered as prime anti-AD compounds [13-15]. From past few years, our research group has been involved in designing and optimizing arecoline derivatives as cholinesterase inhibitors [16-17]. In continuation of our research work [18] in the field of medicinal chemistry for developing more potent and selective AChE/BuChE inhibitors, we have focused our attention to new class of arecoline analogues, by incorporating an extra carbon (-CH₂-) atom between 4-thiazolidinone ring and arecoline nucleus. Synthesis of homologated 4-thiazolidinone substituted arecoline derivatives has been achieved for the first time as shown in the Scheme 1.

METHODS

Reactions were monitored by thin layer chromatography (TLC) using precoated sheets of silica gel G/UV-254 of 0.25 mm thickness (Merck 60F254) using UV light for visualization. ¹H and ¹³C NMR spectra were recorded on an NMR spectrometer operating at 400 and 100 MHz, respectively, using the residual solvent peak as a reference relative to SiMe₄. Mass spectra were recorded using high resolution mass spectrometer (HRMS). Infrared spectra were recorded on Shimadzu FT-IR model 8300 spectrophotometer.

Chemicals used: All chemicals were obtained from Sigma-Aldrich, Fluka and Merck Chemicals.

Synthesis

General procedure for the synthesis of tert-butyl 4-{3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-oxothiazolidin-2-yl}piperidine-1-carboxylate (5)

To an equimolar 3-picolyl amine (1), N-Boc piperidine 4-carbaldehyde (2) and thioglycolic acid (3) in ethyl acetate, T3P® (1.2 equiv) was added at 0°C and stirred the reaction mixture at room temperature for





Fig. 1: Representational¹H NMR and¹³C NMR

3 hrs [19]. The reaction was monitored by TLC. After the completion of the reaction, the mixture was diluted with water and neutralized by adding 10% NaHCO_3 solution. The product was extracted with ethyl acetate (twice) and the combined organic layers were washed with water followed by brine solution. The organic phase was dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to afford the product (4) which was pure enough to do the next step. Compound (4) on stirring for 3 hrs with methyl iodide (2 equiv) in dry acetone at 0°C followed by reduction using sodium borohydride (1.2 equiv) in methanol at -10°C afforded compound (5).

General procedure for the synthesis of compounds 7(a-r)

The key intermediate (6) was synthesized by deprotection of compound (5) using HCl/ether in ether at 0°C. To a stirred solution of compound (6) in dichloromethane, triethyl amine (3 equiv) was added and cooled to 0-5°C, and then benzyl/benzoyl/benzene sulfonyl chloride (1.0 equiv) was added dropwise. The reaction mixture was stirred for 4-5 hrs at room temperature, the reaction was monitored by TLC. After completion of the reaction, the mixture was washed with water followed by brine solution. The organic layer was dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to afford the title compounds 7(a-r) in good yields.



Scheme 1: Synthesis of arecoline 4-thiazolidinone derivatives. R: 7a=C₆H₄SO₂, 7b=4-OCH₃-C₆H₄-SO₂, 7c=4-F-C₆H₄-SO₂, 7d=4-NO₂-C₆H₄-SO₂, 7e=2,4,6-3CH₃-C₆H₂-SO₂, 7f=2,5-2Cl-C₆H₃-SO₂, 7g=3,4,5-3OCH₃-C₆H₂-SO₂, 7h=3-CH₃-C₆H₄-CH₂, 7i=3-CF₃-C₆H₄-SO₂, 7j=3,4-2Cl-C₆H₃-CH₂, 7k=3-NO₂-C₆H₄-CH₂, 7l=3-F-C₆H₄-CO, 7m=2,6-2Cl-C₆H₃-CO, 7n=3-Br-C₆H₄-CO, 7o=4-Cl-C₆H₄-CO, 7p=2-OCH₃-C₆H₄-CO, 7q=3-NO₂-C₆H₄-CO, 7r=4-t-butyl-C₆H₄-CO

3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-2-(1-(phenylsulfonyl)piperidin-4-yl)thiazolidin-4-one (7a)

Yellow gummy liquid Yield: 85% IR γ_{\max} (nujol) 3050, 1650, 1575, 1450, 1375, 1365, 1240, 1162/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 7.74-7.71 (m, 3H, ArH), 7.33-7.28 (m, 2H, ArH), 5.73 (m, 1H, arecoline-C-4H), 4.54-4.50 (d, J =4.2 Hz, 1H, thiazolidinone-CH), 3.85 (s, 2H, arecolinyl-CH₂), 3.76-3.74 (dd, J = 2.8 Hz, 2H, thiazolidinone-CH₂), 3.27-3.24 (m, 4H, piperidine-CH₂), 2.89 (s, 2H, arecoline-C-2H₂), 2.72-2.68 (m, 2H, arecoline-C-6H₂), 2.56-2.51 (m, 1H, piperidine-C-4H), 2.41 (s, 3H, N-CH₃), 2.25-2.20 (m, 2H, arecoline-C-5H₂), 1.78-1.68 (m, 2H, piperidine-CH₂), 1.65-1.52 (m, 2H, piperidine-CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 174.6, 136.2, 135.7, 129.0, 125.6, 123.5, 121.1, 64.4, 52.8, 50.5, 46.0, 43.5, 42.6, 41.9, 38.2, 26.4, 23.0. HRMS (ESI) m/z Calcd for C₂₁H₂₉N₃O₃S₂Na [M+Na]⁺ 458.6033, found 458.6052.

2-(1-((4-methoxyphenyl)sulfonyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7b)

Pale yellow liquid Yield: 86% IR γ_{\max} (nujol) 3045, 1651, 1582, 1448, 1382, 1369, 1320, 1245, 1163/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 7.70-7.67 (d, J = 8.8 Hz, 2H, ArH), 7.01-6.99 (d, J = 8.0 Hz, 2H, ArH), 5.62 (m, 1H, arecoline-C-4 H), 4.48-4.47 (d, J = 3.8 Hz, 1H, thiazolidinone-CH), 3.87 (s, 3H, OCH₃), 3.81 (s, 2H, arecolinyl-CH₂), 3.519-3.512 (dd, J = 2.8 Hz, 2H, thiazolidinone-CH₂), 3.24-3.18 (m, 4H, piperidine-CH₂), 2.84 (s, 2H, arecoline-C-2H₂), 2.62-2.58 (m, 2H, arecoline-C-6H₂), 2.52-2.49 (m, 1H, piperidine-C-4H), 2.39 (s, 3H, N-CH₃), 2.34-1.79 (m, 2H, arecoline-C-5H₂), 1.77-1.39 (m, 4H, piperidine-CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 171.4, 163.0, 129.7, 129.0, 127.6, 123.8, 114.1, 64.3, 55.6, 55.3, 51.2, 46.2, 45.2, 41.8, 38.3, 32.3, 25.3, 23.1. HRMS (ESI) m/z Calcd for C₂₂H₃₁N₃O₄S₂Na [M+Na]⁺ 465.6292, found 465.6301.

2-(1-((4-fluorophenyl)sulfonyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7c)

Pale brown liquid yield: 78% IR γ_{\max} (nujol) 3043, 1648, 1588, 1448, 1385, 1371, 1245, 1163, 1090/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 7.79-7.77 (d, J = 8.0 Hz, 2H, ArH), 7.30-7.20

(m, 2H, ArH), 5.62 (m, 1H, arecoline C-4H), 4.49-4.48 (d, J = 2.8 Hz, 1H, thiazolidinone-CH), 3.86 (s, 2H, arecolinyl-CH₂), 3.80-3.79 (dd, J = 2.4 Hz, 2H, thiazolidinone-CH₂), 3.24-3.20 (m, 2H, piperidine-CH₂), 2.94-2.77 (m, 2H, piperidine-CH₂), 2.57-2.45 (m, 3H, piperidine-C-4H and arecoline-C-2H₂), 2.38 (s, 3H, N-CH₃), 2.33-2.15 (m, 4H, arecoline-CH₂), 1.81-1.66 (m, 2H, piperidine-CH₂), 1.51-1.33 (m, 2H, piperidine-CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 171.4, 166.4, 132.2, 130.3, 130.2, 116.4, 116.2, 64.2, 54.5, 51.2, 46.2, 45.7, 45.3, 38.1, 32.3, 25.4, 23.0. HRMS (ESI) m/z Calcd for C₂₁H₂₈FN₃O₃S₂Na [M+Na]⁺ 476.5937, found 476.5942.

3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-2-(1-((4-nitrophenyl)sulfonyl)piperidin-4-yl)thiazolidin-4-one (7d)

Dark brown liquid yield: 76% IR γ_{\max} (nujol) 3040, 1648, 1587, 1535, 1449, 1385, 1370, 1360, 1242, 1165/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 8.12-8.10 (d, J = 8.0 Hz, 2H, ArH), 7.98-7.96 (d, J = 7.8 Hz, 2H, ArH), 5.64 (m, 1H, arecoline C-4H), 4.51-4.50 (d, J = 3.4 Hz, 1H, thiazolidinone-CH), 3.95 (s, 2H, arecolinyl-CH₂), 3.88-3.87 (dd, J = 2.4 Hz, 2H, thiazolidinone-CH₂), 3.12-2.91 (m, 4H, piperidine-CH₂), 2.82 (s, 2H, arecoline-C-2H₂), 2.52-2.49 (m, 2H, arecoline-C-6H₂), 2.45-2.36 (m, 1H, piperidine-C-4H), 2.31 (s, 3H, N-CH₃), 2.21-2.13 (m, 2H, arecoline-C-5H₂), 1.71-1.52 (m, 4H, piperidine CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 172.0, 148.2, 140.1, 138.2, 129.1, 124.1, 121.2, 62.5, 58.4, 53.9, 48.2, 45.9, 45.6, 36.2, 33.2, 25.5, 22.9. HRMS (ESI) m/z Calcd for C₂₁H₂₈N₄O₅S₂Na [M+Na]⁺ 503.6008, found 503.6016.

2-(1-(mesitylsulfonyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7e)

Pale yellow gummy solid yield: 80% IR γ_{\max} (nujol) 3054, 2987, 1659, 1582, 1448, 1383, 1372, 1251, 1168/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 7.25 (s, 2H, ArH), 5.73-5.69 (m, 1H, arecoline-C-4H), 4.79-4.78 (d, J = 4.0 Hz, 1H, thiazolidinone-CH), 3.91 (s, 2H, arecolinyl-CH₂), 3.95-3.85 (dd, J = 2.8 Hz, 2H, thiazolidinone-CH₂), 3.12-2.82 (m, 4H, piperidine-CH₂), 2.80 (s, 2H, arecoline-C-2H₂), 2.68 (s, 6H, Ar-CH₃), 2.59-2.56 (m, 2H, arecoline-C-6H₂), 2.49-2.42

(m, 1H, piperidine-C-4H), 2.35 (s, 3H, Ar-CH₃), 2.32 (s, 3H, N-CH₃), 2.12-1.96 (m, 2H, arecoline-C-5H₂), 1.62-1.46 (m, 4H, piperidine-CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 170.8, 148.2, 145.1, 139.2, 138.4, 132.8, 121.8, 63.1, 59.6, 55.2, 48.4, 47.2, 45.6, 37.4, 35.2, 24.6, 22.7, 22.6. HRMS (ESI) *m/z* Calcd for C₂₄H₃₅N₃O₃S₂Na [M+Na]⁺ 500.6830, found 500.6856.

2-(1-((2,5-dichlorophenyl)sulfonyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7f)

Pale brown gummy solid yield: 77% IR γ_{\max} (nujol) 3050, 1658, 1576, 1450, 1380, 1367, 1240, 1163, 730/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 8.03 (s, 1H, ArH), 7.46-7.44 (d, *J* = 8.0 Hz, 2H, ArH), 5.68 (s, 1H, arecoline-C-4H), 4.49-4.48 (d, *J* = 4.0 Hz, 1H, thiazolidinone-CH), 3.93 (s, 2H, arecolinyl-CH₂), 3.87-3.86 (dd, *J* = 2.4 Hz, 2H, thiazolidinone-CH₂), 2.87-2.79 (m, 4H, piperidine-CH₂), 2.75 (s, 2H, arecoline-C-2H₂), 2.64-2.51 (m, 3H, piperidine-C-4H and arecoline-C-6H₂), 2.41 (s, 3H, N-CH₃), 2.29-1.99 (m, 2H, arecoline-C-5H₂), 1.72-1.64 (m, 2H, piperidine-CH₂), 1.60-1.49 (m, 2H, piperidine-CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 171.4, 144.0, 137.9, 133.4, 133.1, 130.7, 129.6, 129.3, 123.9, 65.6, 64.5, 54.5, 51.2, 46.3, 45.2, 38.7, 34.2, 25.3, 23.5. HRMS (ESI) *m/z* Calcd for C₂₁H₂₇Cl₂N₃O₃S₂Na [M+Na]⁺ 527.4934, found 527.4945.

3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-2-(1-(3,4,5-trimethoxyphenyl)sulfonyl)piperidin-4-yl)thiazolidin-4-one (7g)

Pale yellow liquid yield: 90% IR γ_{\max} (nujol) 3050, 1657, 1576, 1448, 1381, 1369, 1240, 1210, 1165/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 7.29 (s, 2H, ArH), 5.69-5.68 (m, 1H, arecoline-C-4H), 4.72-4.71 (d, *J* = 4.2 Hz, 1H, thiazolidinone-CH), 3.92 (s, 2H, arecolinyl-CH₂), 3.89-3.85 (dd, *J* = 2.6 Hz, 2H, thiazolidinone-CH₂), 3.88 (s, 9H, OCH₃), 3.52-3.48 (m, 4H, piperidine-CH₂), 2.95 (s, 2H, arecoline-C-2H₂), 2.58-2.48 (m, 2H, arecoline-C-6H₂), 2.36-2.32 (m, 1H, piperidine-C-4H), 2.29 (s, 3H, N-CH₃), 2.14-2.09 (m, 2H, arecoline-C-5H₂), 1.56-1.42 (m, 4H, piperidine-CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 172.5, 171.8, 153.2, 139.8, 136.9, 130.5, 119.9, 112.5, 61.7, 60.1, 57.2, 54.0, 47.5, 45.2, 36.5, 34.9, 25.9, 23.3. HRMS (ESI) *m/z* Calcd for C₂₄H₃₅N₃O₆S₂Na [M+Na]⁺ 548.6812, found 548.6819.

3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-2-(1-(3-methylbenzyl)piperidin-4-yl)thiazolidin-4-one (7h)

Yellow liquid yield: 72% IR γ_{\max} (nujol) 3057, 1658, 1579, 1445, 1383, 1369, 1240, 1167/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 7.27 (s, 1H, ArH), 7.21-7.12 (m, 3H, ArH), 5.78-5.64 (m, 1H, arecoline-C-4H), 4.71-4.59 (d, *J* = 4.2 Hz, 1H, thiazolidinone-CH), 3.61 (s, 2H, arecolinyl-CH₂), 3.49-3.41 (m, 4H, thiazolidinone-CH₂ & benzyl-CH₂), 2.98-2.96 (m, 4H, piperidine-CH₂), 2.81 (s, 2H, arecoline-C-2H₂), 2.57-2.51 (m, 3H, piperidine-CH and arecoline-C-6H₂), 2.38 (s, 3H, Ar-CH₃), 2.34 (s, 3H, N-CH₃), 1.95-1.90 (m, 2H, arecoline-C-5H₂), 1.71-1.53 (m, 4H, piperidine-CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 171.1, 139.2, 138.4, 137.2, 130.4, 129.5, 128.3, 126.1, 121.5, 65.6, 62.2, 59.1, 54.3, 53.7, 48.1, 45.2, 38.1, 35.1, 26.2, 24.2, 21.5. HRMS (ESI) *m/z* Calcd for C₂₂H₃₁N₃O₃S₂Na [M+Na]⁺ 472.6298, found 472.6308.

3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-2-(1-(3-(trifluoromethyl)phenyl)sulfonyl)piperidin-4-yl)thiazolidin-4-one (7i)

Dark brown liquid yield: 76% IR γ_{\max} (nujol) 3051, 1658, 1582, 1448, 1397, 1388, 1369, 1247, 1172/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 8.06 (s, 1H, ArH), 7.89-7.69 (m, 3H, ArH), 5.62-5.59 (m, 1H, arecoline C-4H), 4.64-4.63 (d, *J* = 3.8 Hz, 1H, thiazolidinone-CH), 3.81 (s, 2H, arecolinyl-CH₂), 3.79-3.76 (dd, *J* = 2.6 Hz, 2H, thiazolidinone-CH₂), 3.14-3.02 (m, 4H, piperidine-CH₂), 2.86 (s, 2H, arecoline-C-2H₂), 2.44-2.38 (m, 3H, arecoline-C-6H₂ and piperidine-CH), 2.29 (s, 3H, N-CH₃), 2.12-2.03 (m, 2H, arecoline-C-5H₂), 1.65-1.58 (m, 4H, piperidine-CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 171.4, 141.6, 138.5, 131.5, 130.9, 129.6, 128.1, 125.4, 125.2, 125.1, 125.0, 123.8, 121.5, 62.5, 59.1, 55.2, 48.2, 47.5, 45.2, 37.2, 35.2, 26.2, 23.1. HRMS (ESI) *m/z* Calcd for C₂₂H₂₈F₃N₃O₃S₂Na [M+Na]⁺ 526.6012, found 526.6019.

2-(1-(3,4-dichlorobenzyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7j)

Brown gummy solid yield: 71% IR γ_{\max} (nujol) 3049, 1658, 1586, 1451, 1392, 1369, 1249, 1176, 786/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 7.74-7.72 (d, *J* = 8.2 Hz, 1H, ArH), 7.45 (s, 1H, ArH), 7.28-7.26 (d, *J* = 8.0 Hz, 1H, ArH), 5.66-5.62 (m, 1H, arecoline-C-4H), 4.68-4.67 (d, *J* = 3.6 Hz, 1H, thiazolidinone-CH), 3.89 (s, 2H, arecolinyl-CH₂), 3.78-3.74 (dd, *J* = 2.4 Hz, 2H, thiazolidinone-CH₂), 3.58 (s, 2H, benzyl-CH₂), 3.18-3.12 (m, 4H, piperidine-CH₂), 2.76 (s, 2H, arecoline-C-2H₂), 2.60-2.56 (m, 2H, arecoline-C-6H₂), 2.39-2.36 (m, 1H, piperidine-C-4H), 2.27 (s, 3H, N-CH₃), 2.19-2.16 (m, 2H, arecoline-C-5H₂), 1.61-1.49 (m, 4H, piperidine-CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 170.8, 138.2, 134.8, 132.2, 129.9, 129.6, 129.2, 121.5, 64.9, 62.5, 59.3, 55.4, 54.2, 48.2, 44.8, 37.6, 35.2, 24.5, 23.9. HRMS (ESI) *m/z* Calcd for C₂₂H₂₉Cl₂N₃OSNa [M+Na]⁺ 477.4562, found 477.4569.

3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-2-(1-(3-nitrobenzyl)piperidin-4-yl)thiazolidin-4-one (7k)

Pale yellow gummy solid yield: 70% IR γ_{\max} (nujol) 3037, 1652, 1593, 1541, 1452, 1389, 1378, 1363, 1245, 1165/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 8.12-8.01 (m, 2H, ArH), 7.56-7.51 (m, 2H, ArH), 5.66-5.62 (m, 1H, arecoline-C-4H), 4.56-4.55 (d, *J* = 4.2 Hz, 1H, thiazolidinone-CH), 3.89 (s, 2H, arecolinyl-CH₂), 3.92-3.81 (dd, *J* = 2.2 Hz, 2H, thiazolidinone-CH₂), 3.64 (s, 2H, benzyl-CH₂), 3.17-3.12 (m, 4H, piperidine-CH₂), 2.85 (s, 2H, arecoline-C-2H₂), 2.51-2.46 (m, 2H, arecoline-C-6H₂), 2.35-2.31 (m, 1H, piperidine-C-4H), 2.27 (s, 3H, N-CH₃), 2.22-2.18 (m, 2H, arecoline-C-5H₂), 1.95-1.86 (m, 2H, piperidine-CH₂), 1.56-1.42 (m, 2H, piperidine-CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 171.6, 148.2, 136.9, 136.2, 135.2, 130.2, 125.6, 122.3, 121.6, 64.2, 62.5, 59.2, 55.2, 53.6, 47.8, 37.9, 35.2, 24.8, 23.2. HRMS (ESI) *m/z* Calcd for C₂₂H₃₀N₄O₃SNa [M+Na]⁺ 453.5636, found 453.5642.

2-(1-(3-fluorobenzoyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7l)

Brown gummy solid yield: 80% IR γ_{\max} (nujol) 3037, 1670, 1657, 1589, 1543, 1458, 1391, 1369, 1248, 1168/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 7.38-7.32 (m, 1H, ArH), 7.21-7.16 (m, 2H, ArH), 7.01-6.96 (m, 1H, ArH), 5.64-5.61 (m, 1H, arecoline-C-4H), 4.59-4.55 (d, *J* = 4.4 Hz, 1H, thiazolidinone-CH), 3.87 (s, 2H, arecolinyl-CH₂), 3.74-3.70 (dd, *J* = 2.4 Hz, 2H, thiazolidinone-CH₂), 3.15-3.09 (m, 4H, piperidine-CH₂), 2.80 (s, 2H, arecoline-C-2CH₂), 2.58-2.53 (m, 2H, arecoline-C-6H₂), 2.46-2.43 (m, 1H, piperidine-C-4H), 2.27 (s, 3H, N-CH₃), 2.22-2.17 (m, 2H, arecoline-C-5H₂), 1.58-1.52 (m, 2H, piperidine-CH₂), 1.39-1.35 (m, 2H, piperidine-CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 171.6, 160.8, 138.3, 137.2, 125.9, 124.1, 122.8, 121.2, 65.6, 62.4, 59.3, 55.2, 53.6, 47.4, 42.9, 36.9, 33.8, 25.9, 24.1, 23.8. HRMS (ESI) *m/z* Calcd for C₂₂H₂₈FN₃O₂SNa [M+Na]⁺ 440.5400, found 440.5412.

2-(1-(2,6-dichlorobenzoyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7m)

Dark brown gummy solid yield: 82% IR γ_{\max} (nujol) 3051, 1680, 1661, 1591, 1453, 1397, 1372, 1251, 1176, 789/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 7.37-7.30 (m, 2H, ArH), 7.26-7.25 (m, 1H, ArH), 5.88-5.83 (m, 1H, arecoline-C-4H), 4.68-4.67 (d, *J* = 4.0 Hz, 1H, thiazolidinone-CH), 3.85 (s, 2H, arecolinyl-CH₂), 3.81-3.79 (dd, *J* = 2.4 Hz, 2H, thiazolidinone-CH₂), 3.20-3.16 (m, 4H, piperidine-CH₂), 2.86 (s, 2H, arecoline-C-2H₂), 2.77-2.66 (m, 3H, piperidine-C-4H & arecoline-C-6H₂), 2.33 (s, 3H, N-CH₃), 2.25-2.05 (m, 2H, arecoline-C-5H₂), 1.68-1.26 (m, 4H, piperidine-CH₂); ¹³C NMR (100 MHz, CDCl₃); δ 172.1, 167.9, 136.3, 135.0, 131.6, 131.5, 127.7, 125.8, 65.4, 52.1, 50.1, 46.1, 45.7, 45.3, 38.8, 32.1, 24.1, 23.2. HRMS (ESI) *m/z* Calcd for C₂₂H₂₇Cl₂FN₃O₂SNa [M+Na]⁺ 491.4397, found 491.4405.

2-(1-(3-bromobenzoyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7n)

Pale yellow gummy solid yield: 84% IR γ_{\max} (nujol) 3053, 1684, 1665, 1596, 1453, 1397, 1372, 1254, 1176, 589/cm⁻¹; ¹H NMR

(400 MHz, CDCl₃); δ 8.01 (s, 1H, ArH), 7.89-7.76 (m, 3H, ArH), 5.65-5.63 (m, 1H, arecoline-C-4H), 4.59-4.58 (d, J = 3.8 Hz, 1H, thiazolidinone-CH), 3.96-3.91 (m, 4H, thiazolidinone-CH₂ and arecolinyl-CH₂), 3.36-3.21 (m, 4H, piperidine-CH₂), 2.86 (s, 2H, arecoline-C-2H₂), 2.46-2.41 (m, 3H, piperidine-C-4H and arecoline-C-6H₂), 2.28 (s, 3H, N-CH₃), 2.19-2.16 (m, 2H, arecoline-C-5H₂), 1.48-1.39 (m, 4H, piperidine-CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 172.1, 171.6, 141.2, 138.5, 132.9, 129.9, 129.4, 126.4, 123.1, 121.5, 61.8, 59.6, 55.2, 48.5, 45.2, 44.7, 37.4, 34.3, 26.2, 23.1. HRMS (ESI) m/z Calcd for C₂₂H₂₈BrN₃O₂Na [M+Na]⁺ 501.4456, found 501.4462.

2-(1-(4-chlorobenzoyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7o)

Pale yellow gummy solid yield: 83% IR γ_{\max} (nujol) 3047, 1680, 1661, 1596, 1450, 1397, 1370, 1254, 1176, 789/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 7.88-7.86 (d, J = 8.0 Hz, 2H, ArH), 7.74-7.72 (d, J = 8.2 Hz, 2H, ArH), 5.63-5.61 (m, 1H, arecoline-C-4H), 4.60-4.51 (d, J = 4.0 Hz, 1H, thiazolidinone-CH), 3.81 (s, 2H, arecolinyl-CH₂), 3.79-3.76 (dd, J = 4.0 Hz, 2H, thiazolidinone-CH₂), 3.41-3.37 (m, 4H, piperidine-CH₂), 2.83 (s, 2H, arecoline-C-2H₂), 2.62-2.57 (m, 2H, arecoline-C-6H₂), 2.52-2.49 (m, 1H, piperidine-C-4H), 2.32 (s, 3H, N-CH₃), 2.16-2.08 (m, 2H, arecoline-C-5H₂), 1.47-1.41 (m, 4H, piperidine-CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 170.8, 170.1, 141.2, 137.3, 134.1, 129.7, 128.9, 126.4, 121.2, 62.2, 59.2, 55.2, 48.2, 45.2, 37.2, 35.2, 26.2, 24.2. HRMS (ESI) m/z Calcd for C₂₂H₂₈ClN₃O₂Na [M+Na]⁺ 456.9946, found 456.9952.

2-(1-(2-methoxybenzoyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7p)

Pale brown gummy solid yield: 88% IR γ_{\max} (nujol) 3042, 1682, 1659, 1596, 1448, 1397, 1372, 1254, 1220, 1178/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 7.90-7.84 (m, 2H, ArH), 7.25-7.21 (m, 2H, ArH), 5.63-5.60 (m, 1H, arecoline-C-4H), 4.64-4.63 (d, J = 4.2 Hz, 1H, thiazolidinone-CH), 3.96 (s, 2H, arecolinyl-CH₂), 3.91 (s, 3H, OCH₃), 3.52-3.51 (dd, J = 2.4 Hz, 2H, thiazolidinone-CH₂), 3.29-3.25 (m, 4H, piperidine-CH₂), 2.95 (s, 2H, arecoline-C-2H₂), 2.56-2.51 (m, 2H, arecoline-C-6H₂), 2.48-2.46 (m, 1H, piperidine-C-4H), 2.35 (s, 3H, N-CH₃), 2.22-2.16 (m, 2H, arecoline-C-5H₂), 1.62-1.59 (m, 2H, piperidine-CH₂), 1.36-1.33 (m, 2H, piperidine-CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 172.6, 171.4, 158.2, 138.2, 131.2, 128.5, 127.8, 121.2, 120.6, 112.6, 62.4, 59.2, 56.2, 55.1, 48.2, 45.2, 44.8, 37.2, 35.1, 25.3, 23.2. HRMS (ESI) m/z Calcd for C₂₃H₃₁N₃O₃Na [M+Na]⁺ 452.5755, found 452.5761.

3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-2-(1-(3-nitrobenzoyl)piperidin-4-yl)thiazolidin-4-one (7q)

Pale brown liquid yield: 82% IR γ_{\max} (nujol) 3041, 1682, 1652, 1592, 1540, 1452, 1394, 1381, 1363, 1245, 1168/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 8.51 (s, 1H, ArH), 8.38-8.32 (m, 2H, ArH), 7.76-7.72 (m, 1H, ArH), 5.64-5.61 (m, 1H, arecoline-C-4H), 4.62-4.61 (d, J = 3.8 Hz, 1H, thiazolidinone-CH), 3.88 (s, 2H, arecolinyl-CH₂), 3.69-3.64 (dd, J = 2.4 Hz, 2H, thiazolidinone-CH₂), 3.26-3.20 (m, 4H, piperidine-CH₂), 2.86 (s, 2H, arecoline-C-2H₂), 2.61-2.57 (m, 2H, arecoline-C-6H₂), 2.42-2.38 (m, 1H, piperidine-C-4H), 2.32 (s, 3H, N-CH₃), 2.28-2.24 (m, 2H, arecoline-C-5H₂), 1.52-1.38 (m, 4H, piperidine-CH₂). ¹³C NMR (100 MHz, CDCl₃); δ 173.1, 171.6, 148.2, 138.2, 136.4, 132.9, 129.6, 125.2, 123.4, 121.5, 62.3, 59.2, 56.1, 48.1, 45.1, 44.9, 36.9, 35.2, 26.2, 23.8. HRMS (ESI) m/z Calcd for C₂₂H₂₈N₄O₄Na [M+Na]⁺ 467.5471, found 467.5478.

2-(1-(4-tert-butylbenzoyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7r)

Pale brown gummy solid yield: 86% IR γ_{\max} (nujol) 3045, 1688, 1662, 1597, 2234, 1451, 1399, 1372, 1330, 1254, 1220, 1178/cm⁻¹; ¹H NMR (400 MHz, CDCl₃); δ 8.01-7.99 (d, J = 8.0 Hz, 2H, ArH), 7.46-7.44 (d, J = 7.8 Hz, 2H, ArH), 5.64-5.61 (m, 1H, arecoline-C-4H), 4.63-4.62 (d, J = 3.6 Hz, 1H, thiazolidinone-CH), 3.85 (s, 2H, arecolinyl-CH₂), 3.75-3.71 (dd, J = 2.6 Hz, 2H, thiazolidinone-CH₂), 3.38-3.32 (m, 4H, piperidine-CH₂), 2.85 (s, 2H, arecoline-C-2H₂), 2.62-2.59 (m, 2H, arecoline-C-6H₂), 2.49-2.45 (m, 1H, piperidine-C-4H),

2.34 (s, 3H, N-CH₃), 2.11-2.07 (m, 2H, arecoline-C-5H₂), 1.61-1.41 (m, 4H, piperidine-CH₂), 1.38 (s, 9H, t-butyl-CH₃). ¹³C NMR (100 MHz, CDCl₃); δ 172.9, 171.0, 148.1, 137.6, 136.1, 133.1, 129.1, 125.2, 122.9, 121.1, 62.2, 59.2, 55.1, 48.1, 44.9, 44.1, 37.2, 35.1, 26.2, 24.2. HRMS (ESI) m/z Calcd for C₂₆H₃₇N₃O₂Na [M+Na]⁺ 478.6559, found 478.6565.

Pharmacology

In vitro inhibition studies on human AChE

The assay has been performed according to the guidelines provided in the AChE Assay Kit (DACE-100) purchased from Bio Assay systems #3191 Corporate Place, Hayward, CA 94545, USA. Briefly the assay medium (1 mL) consisted of phosphate buffer (pH 8.0), 50 μ L of 0.01 M DTNB, 10 μ L of enzyme, and 50 μ L of 0.01 M substrate (ACh chloride solution). Briefly, the test compounds were added to the assay solution and pre incubated at 37°C with enzyme for 15 minutes followed by the addition of substrate. The activity was determined by measuring the increase of absorbance at 412 nm at 60 seconds intervals.

In vitro BuChE inhibition assay

The inhibitory activities of the prepared compounds against BuChE were performed by means of the method previously described by Ellman *et al.* [20] using neostigmine as the reference compound. This is based on the reaction of released thiocholine to give a colored product with a chromogenic reagent. The assay was performed in 0.1 M KH₂PO₄/ K₂HPO₄ buffers, pH 8.0, on a Shimadzu 2450 spectrophotometer. Enzyme solutions were prepared to give the concentration of 2.0 unit/ mL. The assay medium contained 0.01 M phosphate buffer (pH 8.0), DTNB, enzyme, and 0.01 M substrate BTC for BuChE. Test compounds were added to the assay medium and pre-incubated with the enzyme for 15 minutes at 37°C followed by the addition of substrate. The activity was determined by measuring the increase of absorbance at 412 nm with 1 minute interval at 37°C. The data was calculated according to the method of Ellman *et al.* [20].

RESULTS AND DISCUSSION

Chemistry

Previously we have reported $\sqrt{\text{ferrite}}$ catalyzed synthesis of arecoline thiazolidinone derivatives [21] and the synthesized compounds were subjected to *in vitro* muscarinic receptor binding studies as well as *in vivo* pharmacological evaluation of memory and learning in male wistar rats, few of them displayed significant activity in *in vitro* and *in vivo* experiments. In continuation of our research work towards the development of the new class of heterocyclic compounds for the treatment of AD, we herein report propylphosphonic anhydride (T3P®) catalyzed synthesis of homologated arecoline thiazolidinone derivatives. Mild reaction condition, ease of workup, easy purification, and good yields are the noteworthy features of this protocol.

Series of piperidine substituted arecoline 4-thiazolidinone derivatives were prepared by five synthetic steps. Cyclocondensation of 3-picolyl amine, thioglycolic acid with N-Boc piperidine 4-carbaldehyde was carried out in the presence of T3P® to afford 4-thiazolidinone at ambient temperature, then the pyridine ring of the compound 4 was reduced to an arecoline nucleus using earlier reported method [21] to get 5. The deprotection of compound 5 was achieved using HCl in ether to get 7. Finally using key intermediate 7 we have synthesized a good number of piperidine substituted arecoline 4-thiazolidinone derivatives 7(a-r) using substituted benzyl/benzoyl/benzene sulfonyl chlorides.

Pharmacology

Cholinesterase inhibitory activity

Research in the previous decades showed that cholinesterases are the leading and potential targets in treating AD. We investigated whether our newly synthesized compounds could inhibit AChE and BuChE. Effect of arecoline derivatives were evaluated against AChE using DACE-100 Quantichrom™ AChE assay kit based on an improved Ellman method, in which thiocholine produced by the action of AChE forms

a yellow color with 5,5'-dithiobis(2-nitrobenzoic acid). Half maximal inhibitory concentrations (IC_{50}) of the compounds 7a-r along with the IC_{50} of positive control neostigmine are summarized in Table 1. We identified compound 7c to be the most potent inhibitor of AChE with the IC_{50} of 6.62 μ M. Additionally, we also investigated the effect of new molecules against BuChE and 7c exhibited as a very good inhibitor with the IC_{50} of 13.78 μ M. Apart from our lead compound 7c, other members of the series displayed significant inhibitory activity against both esterases with variable efficacy. The IC_{50} values for AChE inhibition are ranged from 26.85 to 6.62 μ M and for BuChE from 45.87 to 13.78 μ M respectively. Interestingly, all synthesized compounds are significantly more active towards AChE than BuChE, Some of the derivatives proved to be comparatively selective for AChE than to BuChE (7c > 7r > 7q > 7m.).

Structure-activity relationship (SAR)

SAR can be drawn from the *in vitro* assay for the synthesized derivatives 7(a-r). Among all the synthesized compounds, four derivatives 7c, 7m, 7r and 7q showed good AChE inhibition activity (Table 1), the potency of the molecules follows the order 7c > 7r > 7q > 7m. The remaining derivatives did not show noticeable AChE/BuChE inhibition. The compound 7c displayed most potent activity (IC_{50} 6.62 μ M for AChE and 13.78 μ M for BuChE) which is comparable with the standard neostigmine (IC_{50} 2.05 μ M for AChE and 3.64 μ M for BuChE). Compound 7c has a fluorine atom at para position of benzene sulfonyl group which is substituted to the amine group of the piperidine nucleus. Compounds with benzyl substitution (7h, 7j, 7k) had poor activity against both AChE and BuChE inhibition when compared to benzene sulfonyl and benzoyl derivatives. This suggests that, the presence of carbonyl or sulfonyl group between piperidine and aryl substitution played an important role for AChE/BuChE inhibition. Among the compounds with aryl sulfonyl/benzoyl group as substituents, different compounds exhibited different range of activity based on the atoms/groups attached to the phenyl ring.

CONCLUSION

In the field of drug discovery, enzymes are often serves as excellent targets in designing therapeutic agents for various pathological conditions. The present report focus on the tailoring of cholinesterase inhibitors is targeting the AD. Many researchers have proved that, cognitive behavior can be improved using cholinesterase inhibitors in AD patients. In this study, a new group of arecoline analogues, modified at the junction of Arecoline and 4-thiazolidinone by incorporating an extra carbon linkage have been prepared and all the synthesized

compounds were evaluated for their inhibitory efficacy against AChE and BuChE. We identified 7c as a lead compound with the good inhibitory efficacy against both cholinesterases. This confirms that the fluorine atom on the benzene sulfonyl moiety may have a considerable influence on the cholinesterase activity. Thus, further structural modification of compound 7c can be carried out to develop effective cholinesterase inhibitors.

ACKNOWLEDGMENTS

The authors are grateful to the DST-IFCPAR, BRNS, Govt. of India for financial support to K.S.R. for the project vide NO. IFC/4303-1/2010-11 Dated 22-12-2010, Vide No. 2009/37/40/BRNS/2266 dated 23/11/2009. KSS and CDM thanks UGC and DST for RFSMS and INSPIRE fellowships.

REFERENCES

- Jeong ML, Sandesh S, Jae WP, Noh IC, Woon DC, Jung HC. Ameliorative effect of novel vitamin formula with herbal extracts on scopolamine-induced alzheimer's disease. *Asian J Pharm Clin Res* 2013;6(2):175-9.
- Jagdeep SD, Prasad DN, Avinash CT, Rajiv G. Role of traditional medicine in neuropsychopharmacology. *Asian J Pharm Clin Res* 2009;2(2):72-6.
- Blokland A. Acetylcholine: A neurotransmitter for learning and memory? *Brain Res Brain Res Rev* 1995;21(3):285-300.
- Sine SM. End-plate acetylcholine receptor: Structure, mechanism, pharmacology, and disease. *Physiol Rev* 2012;92(3):1189-234.
- Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, et al. A new therapeutic target in Alzheimer's disease treatment: Attention to butyrylcholinesterase. *Curr Med Res Opin* 2001;17(3):159-65.
- Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM. Acetylcholinesterase inhibitors: Pharmacology and toxicology. *Curr Neuropharmacol* 2013;11(3):315-35.
- Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: A review of progress. *J Neurol Neurosurg Psychiatry* 1999;66(2):137-47.
- Holden M, Kelly C. Use of cholinesterase inhibitors in dementia. *Adv Psychiatr Treat* 2002;8(2):89-96.
- Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development. *J Pharmacol Exp Ther* 2003;306(3):821-7.
- Murray AP, Faraoni MB, Castro MJ, Alza NP, Cavallaro V. Natural AChE Inhibitors from Plants and their Contribution to Alzheimer's Disease Therapy. *Curr Neuropharmacol* 2013;11(4):388-413.
- Tricco AC, Soobiah C, Berliner S, Ho JM, Ng CH, Ashoor HM, et al. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: A systematic review and meta-analysis. *Can Med Assoc J* 2013;185(16):1393-401.
- Adams RL, Craig PL, Parsons OA. Neuropsychology of dementia. *Neurol Clin* 1986;4(2):387-404.
- Chang YF, Liu TY, Liu ST. Arecoline inhibits and destabilizes agrin-induced acetylcholine receptor cluster formation in C2C12 myotubes. *Food Chem Toxicol* 2013;60:391-6.
- Bartolomeo AC, Morris H, Boast CA. Arecoline via miniosmotic pump improves AF64A-impaired radial maze performance in rats: A possible model of Alzheimer's disease. *Neurobiol Learn Mem* 1997;68(3):333-42.
- Asthana S, Greig NH, Holloway HW, Raffaele KC, Berardi A, Schapiro MB, et al. Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease. *Clin Pharmacol Ther* 1996;60(3):276-82.
- Sadashiva CT, Chandra JN, Kavitha CV, Thimmegowda A, Subhash MN, Rangappa KS. Synthesis and pharmacological evaluation of novel N-alkyl/aryl substituted thiazolidinone arecoline analogues as muscarinic receptor 1 agonist in Alzheimer's dementia models. *Eur J Med Chem* 2009;44(12):4848-54.
- Malviya M, Kumar YC, Mythri RB, Venkateshappa C, Subhash MN, Rangappa KS. Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models. *Bioorg Med Chem* 2009;17(15):5526-34.
- Sharath Kumar KS, Hanumappa A, Hegde M, Narasimhamurthy KH, Raghavan SC, Rangappa KS. Synthesis and antiproliferative effect of novel 4-thiazolidinone-, pyridine- and piperazine-based conjugates on human leukemic cells. *Eur J Med Chem* 2014;81:341-9.

Table 1: Inhibitory activity of arecoline-thiazolidinone derivatives 7a-r and positive control against AChE and BuChE, determined by Ellman's method

Compounds	IC_{50} for AChE (μ M)	IC_{50} for BuChE (μ M)
7a	26.85466 \pm 1.94	45.87 \pm 1.0
7b	23.7816 \pm 1.09	40.08 \pm 1.06
7c	6.62 \pm 0.41	13.78 \pm 0.48
7d	20.98246 \pm 0.69	22.71 \pm 1.68
7e	27.81 \pm 1.03	36.17 \pm 0.64
7f	28.08 \pm 1.74	30.44 \pm 1.4
7g	24.21 \pm 2.8	20.40 \pm 2.19
7h	41.28063 \pm 1.75	53.36 \pm 0.77
7i	32.61538 \pm 2.35	ND
7j	34.7554 \pm 0.55	25.80 \pm 2.18
7k	30.36954 \pm 1.57	ND
7l	ND	ND
7m	19.90476 \pm 0.56	21.93 \pm 0.81
7n	26.6911 \pm 2.12	38.08 \pm 2.81
7o	25.81726 \pm 1	33.94 \pm 0.65
7p	21.9312 \pm 1.49	24.33 \pm 1.23
7q	16.28019 \pm 0.43	19.03 \pm 2.79
7r	11.57143 \pm 0.87	25.93 \pm 1.71
Neostigmine	2.051282 \pm 0.07	3.64 \pm 0.19

AChE: Acetylcholinesterase, BuChE: Butyrylcholinesterase

19. Sharath Kumar KS, Swaroop TR, Harsha KB, Narasimhamurthy KH, Rangappa KS. T₃P®-DMSO mediated one pot cascade protocol for the synthesis of 4-thiazolidinones from alcohols. *Tetrahedron Lett* 2012;53:5619-23.
20. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol* 1961;7:88-95.
21. Chandra JN, Malviya M, Sadashiva CT, Subhash MN, Rangappa KS. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models. *Neurochem Int* 2008;52(3):376-83.